Study Seeking Patients with Post Traumatic Stress Disorder (PTSD)

  • sponsor
Updated on 25 March 2021


Study Seeking Patients with Post Traumatic Stress Disorder (PTSD)


A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole (1-3 mg/day) as Monotherapy or as Combination Therapy in the Treatment of Adults with Post-traumatic Stress Disorder

Condition Post-Traumatic Stress Disorders, Mental Disability
Clinical Study IdentifierTX148345
Last Modified on25 March 2021


Yes No Not Sure

Inclusion Criteria

Male or female age 18 to 65 years
PTSD as the primary psychiatric diagnosis
Onset of PTSD symptoms at least 6 months prior to screening

Exclusion Criteria

Currently receiving disability payments because of PTSD or any other psychiatric disorder; unless the disability payments will not be impacted by potential improvements demonstrated in the trial
The index traumatic event took place >15 years before screening
Initial onset of trauma occurred before age 16
Subjects with PTSD who are considered resistant/refractory to psychotropic treatment by history
Currently receiving Zoloft with adequate dose and duration (> 50 mg/day for a minimum of 8 weeks)
Currently meets criteria for a Major Depressive Episode (ie, currently symptomatic)
Current or recent history (within 6 months prior to the Screening Visit) of an anxiety disorder (i.e. GAD, OCD etc) which was the primary focus of treatment
DSM-5 diagnosis of any other major psychiatric disorder
Current diagnosis or history of substance or alcohol use disorder (excluding nicotine) (DSM-5 criteria) 120 days prior to the Screening Visit
Positive urine drug screen
History of moderate or severe head trauma or other neurological disorders or systemic medical diseases
Experienced a traumatic event within 3 months prior to screening
Suicide attempt or active suicidal ideation in the last 90 days
Insulin-dependent diabetes mellitus (IDDM) (ie, any subjects using insulin)
Uncontrolled hypertension or symptomatic hypotension; uncontrolled hyper or hypothyroidism
Epilepsy or a history of seizures, except for a single seizure episode
Received brexpiprazole in any prior clinical trial or currently taking commercially available brexpiprazole (Rexulti®)
Participated in a clinical trial within the last 60 days or more than 2 clinical trials within the past year
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note